Citadel Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-600
| Closed | -$9.44K | – | 15772 |
|
|
2024
Q1 | $9.44K | Sell |
600
-4,800
| -89% | -$73.9K | ﹤0.01% | 13497 |
|
|
2023
Q4 | $87.1K | Buy |
5,400
+4,500
| +500% | +$57.4K | ﹤0.01% | 11108 |
|
|
2023
Q3 | $11.4K | Buy |
+900
| New | +$12.4K | ﹤0.01% | 13009 |
|
|
2023
Q2 | – | Sell |
-12,800
| Closed | -$198K | – | 15472 |
|
|
2023
Q1 | $198K | Buy |
12,800
+12,400
| +3,100% | +$207K | ﹤0.01% | 10205 |
|
|
2022
Q4 | $6.56K | Buy |
+400
| New | +$6.5K | ﹤0.01% | 13904 |
|
|
2022
Q1 | – | Sell |
-32,500
| Closed | -$318K | – | 14836 |
|
|
2021
Q4 | $318K | Buy |
+32,500
| New | +$611K | ﹤0.01% | 10797 |
|
|
2021
Q3 | – | Sell |
-14,200
| Closed | -$520K | – | 14879 |
|
|
2021
Q2 | $520K | Buy |
14,200
+400
| +3% | +$15.5K | ﹤0.01% | 9988 |
|
|
2021
Q1 | $619K | Sell |
13,800
-3,600
| -21% | -$168K | ﹤0.01% | 9224 |
|
|
2020
Q4 | $993K | Sell |
17,400
-5,600
| -24% | -$332K | ﹤0.01% | 6807 |
|
|
2020
Q3 | $1.18M | Buy |
23,000
+8,400
| +58% | +$411K | ﹤0.01% | 5730 |
|
|
2020
Q2 | $872K | Sell |
14,600
-23,400
| -62% | -$1.25M | ﹤0.01% | 6076 |
|
|
2020
Q1 | $1.56M | Sell |
38,000
-35,700
| -48% | -$1.98M | ﹤0.01% | 4546 |
|
|
2019
Q4 | $4.59M | Buy |
73,700
+44,700
| +154% | +$2.12M | ﹤0.01% | 3181 |
|
|
2019
Q3 | $984K | Buy |
+29,000
| New | +$858K | ﹤0.01% | 5623 |
|
Other funds holding DCPH
Citadel Advisors's DCPH Position: Q2 2024 in Review
Citadel Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 110,550 shares — an estimated $1.74M sold.
Citadel Advisors first reported a position in DCPH in Q3 2017 and held it in 25 quarters. The position peaked at $17.6M in Q1 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Citadel Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 110,550 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.74M.
- Citadel Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 25 quarters.
- Citadel Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $17.6M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.